Skip to content

Kite Pharma releases data on lead leukemia med

June 8, 2017

Kite Pharma, Inc. KITE announced results from phase I trial, ZUMA-3, on lead candidateKTE-C19 (axicabtagene ciloleucel) in adults with high burden relapsed/refractory acute lymphoblastic leukemia (r/r ALL). The results showed that  73% of patients achieved complete remission, including those with incomplete or partial recovery of bone marrow, in adults with high burden relapsed/refractory acute lymphoblastic leukemia (r/r ALL). The results were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Notably, KTE-C19 is the company’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy.

http://bit.ly/2r4wLCH

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: